(AVBP) ArriVent BioPharma, Common - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.258m USD | Total Return: 29.6% in 12m
Avg Turnover: 10.9M
Warnings
Share dilution 32.9% YoY
Interest Coverage Ratio -1.4 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
ArriVent BioPharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies. Its lead candidate, firmonertinib, is a tyrosine kinase inhibitor currently in Phase 3 trials for non-small cell lung cancer (NSCLC) involving exon 20 insertion mutations, alongside Phase 1b evaluations for other EGFR mutations. The company’s pipeline also includes antibody-drug conjugates (ADCs) and small molecules targeting gastrointestinal cancers and various solid tumors.
The biotechnology sector often relies on strategic licensing and cross-border collaborations to accelerate drug development, as evidenced by ArriVent’s partnerships with several Chinese pharmaceutical entities. Clinical-stage firms typically operate with high research and development expenses and no product revenue, making the success of lead candidates like firmonertinib critical to long-term valuation. Investors may find it beneficial to monitor clinical trial milestones and regulatory filings through ValueRay to assess ongoing risk.
- Phase 3 trial data for firmonertinib determines market entry in NSCLC
- FDA approval timing for exon 20 insertion mutations drives valuation
- Expansion of firmonertinib into PACC mutations broadens the addressable patient population
- Clinical progress of ARR-217 antibody drug conjugate impacts long-term pipeline value
- Strategic partnership milestones with Allist Pharmaceuticals influence cash runway and development costs
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA 17.00 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.38 > 3% & CFO -134.5m > Net Income -145.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.1m) vs 12m ago 32.95% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -1.41 > 6 (EBITDA TTM -156.9m / Interest Expense TTM 111.6m) |
| A: 0.93 (Total Current Assets 348.7m - Total Current Liabilities 25.0m) / Total Assets 349.3m |
| B: -1.28 (Retained Earnings -448.0m / Total Assets 349.3m) |
| C: -0.56 (EBIT TTM -156.9m / Avg Total Assets 282.4m) |
| D: -17.71 (Book Value of Equity -448.2m / Total Liabilities 25.3m) |
| Altman-Z'' = -20.43 = D |
As of May 24, 2026, the stock is trading at USD 26.73 with a total of 425,358 shares traded.
Over the past week, the price has changed by -4.09%,
over one month by -13.48%,
over three months by +13.84% and
over the past year by +29.57%.
ArriVent BioPharma, Common has received a consensus analysts rating of 4.86. Therefore, it is recommended to buy AVBP.
- StrongBuy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 41.9 | 56.9% |
Revenue TTM = 0.0 USD
EBIT TTM = -156.9m USD
EBITDA TTM = -156.9m USD
Long Term Debt = 320k USD (estimated: total debt 419k - short term 99.0k)
Short Term Debt = 99.0k USD (from shortTermDebt, last quarter)
Debt = 419k USD (from shortLongTermDebtTotal, last quarter) (leases 419k already included)
Net Debt = -326.0m USD (calculated: Debt 419k - CCE 326.4m)
Enterprise Value = 931.6m USD (1.26b + Debt 419k - CCE 326.4m)
Interest Coverage Ratio = -1.41 (Ebit TTM -156.9m / Interest Expense TTM 111.6m)
EV/FCF = -6.93x (Enterprise Value 931.6m / FCF TTM -134.5m)
FCF Yield = -14.44% (FCF TTM -134.5m / Enterprise Value 931.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.67 (Enterprise Value 931.6m / Total Assets 349.3m)
Interest Expense / Debt = 26.6k% (Interest Expense 111.6m / Debt 419k)
Taxrate = 21.0% (US default 21%)
NOPAT = -123.9m (EBIT -156.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.95 (Total Current Assets 348.7m / Total Current Liabilities 25.0m)
Debt / Equity = 0.00 (Debt 419k / totalStockholderEquity, last quarter 324.0m)
Debt / EBITDA = 2.08 (negative EBITDA) (Net Debt -326.0m / EBITDA -156.9m)
Debt / FCF = 2.42 (negative FCF - burning cash) (Net Debt -326.0m / FCF TTM -134.5m)
Total Stockholder Equity = 296.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.43% (Net Income -145.2m / Total Assets 349.3m)
RoE = -19.51% (Net Income TTM -145.2m / Total Stockholder Equity 744.5m)
RoCE = -21.06% (EBIT -156.9m / Capital Employed (Equity 744.5m + L.T.Debt 320k))
RoIC = -72.37% (negative operating profit) (NOPAT -123.9m / Invested Capital 171.2m)
WACC = 8.51% (E(1.26b)/V(1.26b) * Re(8.51%) + (debt cost/tax rate unavailable))
Discount Rate = 8.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.21 | Cagr: 14.10%
[DCF] Fair Price = unknown (Cash Flow -134.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.14 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.98 | Chg30d=-15.02% | Revisions=-50% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-1.00 | Chg30d=-8.86% | Revisions=-25% | Analysts=7
EPS current Year (2026-12-31): EPS=-4.01 | Chg30d=-6.49% | Revisions=-20% | GrowthEPS=+7.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.37 | Chg30d=-2.89% | Revisions=-11% | GrowthEPS=+15.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -50%